This week in therapeutics




Licensing status

Publication and contact information

Infectious disease


Plasmodium cytochrome bc1

Mouse and cell culture studies suggest the 4(1H)-quinolone-3-diarylether ELQ-300 could help treat liver- and blood-stage malaria infections. In a panel of Plasmodium falciparum and P. vivax clinical isolates, including those that were drug resistant, ELQ-300 showed antiplasmodial activity with single-digit nanomolar IC50 values. In mouse models for blood- and liver-stage P. berghei or P. yoelii infection, oral treatment with ELQ-300 decreased parasitemia and levels of liver-stage parasites compared with vehicle treatment. Next steps could include evaluating ELQ-300 in nonhuman primate models for malaria infection.
Medicines for Malaria Venture has ELQ-300 in preclinical development.

SciBX 6(13); doi:10.1038/scibx.2013.313
Published online April 4, 2013

Patent applications filed; licensing status unavailable

Nilsen, A. et al. Sci. Transl. Med.; published online March 20, 2013;
Contact: Michael K. Riscoe, Portland VA Medical Center, Portland, Ore.
Contact: Roman Manetsch, University of South Florida, Tampa, Fla.